Immunomedics Introduces New Antibody-Drug Conjugate at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of Hematology

-- Demonstrates Broad Activity Against Four Blood Cancers --

-- Underscores Strategic Progress on Near-Term Milestones --

SAN DIEGO, Dec. 06, 2016 (GLOBE NEWSWIRE) --   Immunomedics, Inc. (NASDAQ: IMMU ) today announced that IMMU-140, the Company’s latest investigational product from its award-winning antibody-drug conjugate (ADC) program, demonstrated a significant antitumor effect without any undue toxicity in four hematopoietic tumors in preclinical studies.

Cynthia L. Sullivan, President and Chief Executive Officer, said, “The positive results of IMMU-140 announced today, together with our continued progress on IMMU-132 and other treatments, strongly affirm Immunomedics’ robust product development pipeline and the many value creation opportunities that are possible in the near-term. We are highly focused on achieving upcoming milestones and realizing these opportunities, which we expect to create benefits for patients and Immunomedics’ stockholders alike.”

IMMU-140 comprises the humanized antibody, IMMU-114, conjugated to the moderately-toxic drug, SN-38, through the Company’s proprietary linker, CL2A, the same toxic payload and antibody-drug linker that are in sacituzumab govitecan (IMMU-132). The latter ADC has produced encouraging results in a Phase 2 study in patients with metastatic triple-negative breast cancer (TNBC) and has been designated a Breakthrough Therapy by the FDA for TNBC patients who have received at least two prior therapies for their late-stage disease.

IMMU-114, the parental antibody of IMMU-140, is an anti-HLA-DR IgG4 antibody engineered to lack effector-cell functions, but retains binding and a broad range of antitumor effects in diverse hematological neoplasms. 1 When given subcutaneously, it has encouraging efficacy in a Phase 1 first-in-man study in patients with advanced, relapsed, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with a good safety profile. In contrast, acute myelocytic leukemia (AML), despite high expression levels of HLA-DR, has proven to be resistant to the antitumor effects of IMMU-114 in vitro . As a result, AML, along with acute lymphocytic leukemia (ALL) and multiple myeloma (MM), continue to be a therapy challenge.

The goal of this preclinical study was to determine if SN-38, a drug not commonly used in liquid malignancies, would prove to be an effective and safe therapeutic when targeted with the IMMU-114 antibody, which could then improve the antitumor activity of IMMU-114. A total of four human cancer cell lines, AML, ALL, MM, and CLL, were used to examine the in vitro and in vivo activity of IMMU-140 versus parental IMMU-114.

In a mouse model of human AML, animals treated with 500 µg of IMMU-140 had a significant increase in survival compared to control mice. A dose-reduction of IMMU-140 to 250 µg still offered a greater than 90% improvement in survival compared to saline. In the ALL model, although mice treated with IMMU-114 had a significant improvement in survival compared with untreated animals, IMMU-140 treatment provided a significantly improved survival benefit above that achieved with IMMU-114 therapy.

Mice bearing human MM had a median survival time (MST) that was about a 60% improvement when compared to IMMU-114 therapy. In CLL, both IMMU-140 and IMMU-114 produced a similarly improved MST. Therapy with IMMU-140 was well tolerated by the mice with no appreciable loss in body weight.

“Through the antitumor activity mediated directly by IMMU-114 and the added cytotoxic effect of SN-38 delivery to the tumor cells, we believe IMMU-140 provides an added benefit as a dual-therapeutic,” remarked Ms. Sullivan. “These preclinical results demonstrated IMMU-140’s higher potency than naked IMMU-114 in ALL and AML, and an added, if not significant, survival benefit in experimental MM and CLL. More importantly, the dual-therapeutic potential of IMMU-140 allows for the ability to treat a range of HLA-DR-positive hematopoietic and solid cancers, and therefore warrants further clinical development.”

Ms. Sullivan added, “This is the third ADC based on our proprietary SN-38 platform technology, which we believe will prove to be an important contribution to the management of patients with several refractive liquid tumors, in addition to an interesting list of solid cancers that are under study.”

Reference

  1. Stein R, Gupta P, Chen X, et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood, 115(25):5180-90, 2010. 

About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 302 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 ccheng@immunomedics.com Media Dan Katcher / Ed Trissel / Nick Lamplough Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 Investors Dan Burch/Bob Marese MacKenzie Partners, Inc. (212) 929-5500

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 124

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 51

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 87

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 79

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 34

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 34

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 38

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading

Top 5 Most Recently Viewed Articles

What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 219

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
Saab Expands Military Partnerships with New Colombian Contract

Updated Category News Views 381

Saab's New Military Contract with Colombia In a significant development for both Saab and the Colombian government, the defense company has successfully secured a contract to supply 17 Gripen E/F fighter aircraft. This milestone order, valued at approximately EUR 3.1 billion, is set to bolster Colombia's air defense capabilities over the coming years. Details of the...

Continue Reading
Senske Family of Companies Strengthens Canadian Services with Acquisitions

Updated Category News Views 187

Senske Family of Companies Strengthens Canadian Services with Acquisitions Senske Family of Companies (SFC) is thrilled to announce its latest expansion by acquiring two notable Nutri-Lawn franchise operations, enhancing its presence and service capabilities. Details of the Acquisitions The newly acquired franchises, Nutri-Lawn Mississauga and Nutri-Lawn Fredericton,...

Continue Reading
Understanding Sunstone Hotel Investors' 2024 Dividend Tax Breakdown

Updated Category News Views 171

Tax Treatment of 2024 Dividends by Sunstone Hotel Investors Sunstone Hotel Investors, Inc. (NYSE: SHO) has provided important insights regarding the tax implications for its 2024 dividend distributions. This announcement is pivotal for shareholders who need to understand the tax treatment applicable to their dividends, particularly as it relates to their income tax...

Continue Reading
Strategizing with BABA: A Comprehensive Butterfly Trade Guide

Updated Category News Views 179

Navigating the Financial Waters with a Double Butterfly Trade In today's complex economic landscape, characterized by mixed signals, investors need to stay agile and informed. While initial public offerings (IPOs) have seen a decline, private equity investment is on the rise. Housing trends are juxtaposed, with new housing starts dropping yet home sales increasing. In the...

Continue Reading